Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
23 04 2019
Historique:
received: 13 09 2018
accepted: 23 02 2019
entrez: 17 4 2019
pubmed: 17 4 2019
medline: 15 5 2020
Statut: ppublish

Résumé

Prostate apoptosis response 4 (Par-4) is a tumor suppressor that prevents proliferation and induces cell death in several solid tumors. However, its role in B-cell malignancies has not been elucidated. To describe the role of Par-4 in chronic lymphocytic leukemia (CLL) pathogenesis, we developed a B-cell-specific human Par-4-overexpressing mouse model of CLL using the TCL1 leukemia model. While Par-4 transgenic mice did not display any obvious defects in B-cell development or function, disease burden as evidenced by abundance of CD19

Identifiants

pubmed: 30987970
pii: bloodadvances.2018025973
doi: 10.1182/bloodadvances.2018025973
pmc: PMC6482354
doi:

Substances chimiques

Apoptosis Regulatory Proteins 0
Proto-Oncogene Proteins 0
TCL1A protein, human 0
Tumor Suppressor Proteins 0
prostate apoptosis response-4 protein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1255-1266

Subventions

Organisme : NCI NIH HHS
ID : R01 CA197844
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA159296
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA165469
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197734
Pays : United States

Informations de copyright

© 2019 by The American Society of Hematology.

Références

J Cell Physiol. 2012 Dec;227(12):3715-21
pubmed: 22552839
J Biol Chem. 2005 Jun 17;280(24):23363-70
pubmed: 15831492
Blood. 2018 Jun 28;131(26):2943-2954
pubmed: 29695515
Oncotarget. 2016 Jun 28;7(26):39458-39472
pubmed: 27223062
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Folia Histochem Cytobiol. 2011;49(1):98-103
pubmed: 21526495
Eur J Cancer. 2010 Mar;46(4):800-10
pubmed: 20045309
Mol Cell. 2005 Oct 7;20(1):33-44
pubmed: 16209943
J Cancer Res Clin Oncol. 2000 Apr;126(4):226-32
pubmed: 10782896
Leukemia. 2014 Jul;28(7):1501-10
pubmed: 24445867
Cancer Res. 2002 Mar 15;62(6):1768-75
pubmed: 11912153
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Immunol. 2000 Feb 15;164(4):2200-6
pubmed: 10657675
EMBO Rep. 2005 Jun;6(6):577-83
pubmed: 15877079
Blood Adv. 2017 Nov 09;1(24):2257-2268
pubmed: 29296874
Mol Cancer. 2010 Apr 30;9:98
pubmed: 20433755
Blood. 2018 Mar 22;131(12):1337-1349
pubmed: 29352038
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60
pubmed: 12011454
Cancer Discov. 2014 Dec;4(12):1448-65
pubmed: 25252690
Hematol J. 2001;2(2):103-7
pubmed: 11424002
Cancer Res. 2007 Mar 1;67(5):1927-34
pubmed: 17332319
Leukemia. 2004 Aug;18(8):1391-400
pubmed: 15175625
J Biol Chem. 2003 May 30;278(22):19995-20005
pubmed: 12644474
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Leukemia. 2017 Jun;31(6):1333-1339
pubmed: 27904138
Am J Hematol. 2004 Jan;75(1):22-33
pubmed: 14695629
Mol Cell Biol. 2005 Feb;25(3):1146-61
pubmed: 15657440
Leukemia. 2015 Feb;29(2):346-55
pubmed: 24947019
J Immunol. 2006 Feb 15;176(4):2208-18
pubmed: 16455977
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19643-8
pubmed: 19064921
Oncogene. 2007 Feb 22;26(8):1166-77
pubmed: 16924235
EMBO Rep. 2003 Mar;4(3):307-12
pubmed: 12634851
FEBS Lett. 2002 Jan 2;510(1-2):57-61
pubmed: 11755531
Am J Physiol Cell Physiol. 2011 Apr;300(4):C723-42
pubmed: 21209361
Cancer Res. 2007 Oct 1;67(19):9276-85
pubmed: 17909035
Cell Death Dis. 2014 Jan 23;5:e1016
pubmed: 24457960
Cancer Res. 2006 Apr 1;66(7):3456-62
pubmed: 16585168
Blood. 2009 Jul 30;114(5):1029-37
pubmed: 19491390
J Biol Chem. 1999 Oct 15;274(42):29976-83
pubmed: 10514481
Cell. 1996 Sep 6;86(5):777-86
pubmed: 8797824
Blood. 2012 Jan 5;119(1):180-7
pubmed: 22065599
EMBO J. 2003 Sep 15;22(18):4689-98
pubmed: 12970181
Mol Biol Cell. 2009 Sep;20(18):4010-20
pubmed: 19625447
Mol Cell Biol. 2003 Aug;23(16):5516-25
pubmed: 12897127
Oncogene. 1999 Jan 21;18(3):623-31
pubmed: 9989812

Auteurs

J T Greene (JT)

The James Comprehensive Cancer Center and.

Rajeswaran Mani (R)

The James Comprehensive Cancer Center and.

Rahul Ramaswamy (R)

The James Comprehensive Cancer Center and.

Frank Frissora (F)

The James Comprehensive Cancer Center and.

Max Yano (M)

The James Comprehensive Cancer Center and.

Kevan Zapolnik (K)

The James Comprehensive Cancer Center and.

Bonnie Harrington (B)

The James Comprehensive Cancer Center and.

Ronni Wasmuth (R)

The James Comprehensive Cancer Center and.

Minh Tran (M)

The James Comprehensive Cancer Center and.

Xiaokui Mo (X)

Center for Biostatistics, The Ohio State University, Columbus, OH; and.

Mary McKenna (M)

Markey Cancer Center, University of Kentucky, Lexington, KY.

Vivek M Rangnekar (VM)

Markey Cancer Center, University of Kentucky, Lexington, KY.

John C Byrd (JC)

The James Comprehensive Cancer Center and.

Subbarao Bondada (S)

Markey Cancer Center, University of Kentucky, Lexington, KY.

Natarajan Muthusamy (N)

The James Comprehensive Cancer Center and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH